ORMDL3

Across TCGA pan-cancer cohorts, ORMDL3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ORMDL3 data layer compared with 29 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ORMDL3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ORMDL3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where ORMDL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.311	0.857	.006	30	view →
LUAD	DFS	Tertile	III,IV	0.980	0.575	.020	6	view →
LSCC	DFS	Quartile	II,III,IV	0.961	0.710	.030	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ORMDL3–HNSC (DFS)

Open the HNSC breakdown →